Fisher & Paykel Healthcare (FRA:FPLB) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FPLB Fisher & Paykel Healthcare Corp Ltd FRA:FPLB
87 GF Score
Price €20.00
GF Value €21.76
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:FPLB
87GF Score
Fisher & Paykel Healthcare Corp Ltd FRA:FPLB
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fisher & Paykel Healthcare (FRA:FPLB) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of €20.00 is trading 8.1% below its estimated GF Value™ of €21.76. GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.

Key valuation signals for FRA:FPLB:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €21.76 vs. price of €20.00 (8.1% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the FRA:FPLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
87GF Score

Get the complete analysis for FRA:FPLB

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.00
Price
€21.76
GF Value